BÜLENT YALÇIN

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

Safa Can Efil, Fatih Kus, Bahadir Koylu, Bekir Mert Durukan et autres

BACKGROUND: Durvalumab combined with gemcitabine-cisplatin (GC) has become the standard first-line treatment for advanced biliary tract cancer (BTC) following the TOPAZ-1 trial. However, real-world effectiveness, safety, and prognostic determinants, particularly in underrepresented populations, remain insufficiently defined. The aim of this study was …

tr, ag (code pays fourni par la source)

IMMUNOTHERAPY FOR RARE SOLID TUMORS AND SARCOMAS

İrfan Karahan, Seda Kahraman, BÜLENT YALÇIN

İMMÜNOTERAPİLERİN YAN ETKİ YÖNETİMİ

Emre Hafizoglu, BÜLENT YALÇIN

Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data

O. Berna Oksuzoglu, SERCAN AKSOY, Burak Yasin Aktaş, Ibrahim Karadag et autres

Purpose: Recently, neoadjuvant treatment approach has gained importance in locally advanced HER-2 positive breast cancer. Adding pertuzumab increases pathological complete response (pCR). In this study, we aimed to examine the clinicopathologic features that predict the pCR in patients receiving neoadjuvant pertuzumab, trastuzumab, …

Hepato-Pankreato Biliyer Sistem Kanserleri

Muhammed Bulent Akinci, BÜLENT YALÇIN, Mutlu HIZAL

PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)

Abdullah Sakin, P. Kubilay, Orhan Önder Eren, DENİZ TATAROĞLU ÖZYÜKSELER et autres

The incidence and prognostıc significance of sarcopenia in advanced gastric cancer patients

Mutlu HIZAL, Oğuzcan Gümüşçubuk, MEHMET ALİ NAHİT ŞENDUR, Didem Şener Dede et autres

The investigation of the related factors that affected targeted therapy outcome in metastatic colon cancer

BURAK BİLGİN, ŞENİZ TUTUM, Muhammed Bulent Akinci, MEHMET ALİ NAHİT ŞENDUR et autres

THE INCIDENCE AND PROGNOSTICSIGNIFICANCE OF SARCOPENIA IN ADVANCEDGASTRIC CANCER PATIENTS

Didem Şener Dede, MEHMET ALİ NAHİT ŞENDUR, BÜLENT YALÇIN, Muhammed Bulent Akinci et autres

PROGNOSTIC AND PREDICTIVE MARKERSOF FOLFIRI/AFLIBERCEPT IN PATIENTS WITHMETASTATIC COLORECTAL CANCER (TOG STUDY)Cihan Erol1, Mutlu Hızal2, Irem Bilgetekin3, Sinem Akbas4,Duygu Bayir Garbioglu5, Jamshid Hamdard6, Cagatay Arslan7,Alper Sevinc8, Ahmet Kucukarda9, Dilek Gurgenyatagi10, EmreCakir11, Aykut Demirkiran12, Murat Araz12, Sercan On13, IzzetDogan14, Atike Pinar Erdogan15, Sinan Koca16, Pinar Kubilay17,Onder Eren18, Deniz Tataroglu Ozyukseler19, Mahmut EmreYildirim19, Ebru Cilbir20, Emir Celik21, Aykut Bahceci22, HalilTaskaynatan23, Abdulkerim Oyman24, Gulhan Ipek Deniz25,Serkan Menenekse26, Engin Kut26, Ahmet Gulmez27, AbdullahSakin28, Erdinc Nayir29, Ramazan Acar30, Seda Kahraman1,Erdem Sen31, Ali Inal32, Serdar Turhal33, Ali Osman Kaya34, SemraPaydas35, Didem Tastekin14, Ilhan Hacıbekiroglu11, Irfan Cicin9,Ahmet Bilici6, Didem Sener Dede1, Muhammed Bulent Akinci1,Nil Molinas Mandel36, Berna Oksuzoglu3, Dogan Uncu2, BulentYalcin1, Mehmet Artac12, Mehmet Ali Nahit Sendur1

Mutlu HIZAL, Cihan Erol, SİNEM AKBAŞ, BÜLENT YALÇIN et autres

Malign Glial Tümörlerin Klinikopatolojik Özellikleri ve Sağkalim Verilerinin İncelenmesi

Karabekır Ercan, BÜLENT YALÇIN, Didem Şener Dede, MEHMET ALİ NAHİT ŞENDUR et autres

MALİGN GLİAL TÜMÖRLERİN KLİNİKOPATOLOJİK ÖZELLİKLERİ VE SAĞKALIM VERİLERİNİN İNCELENMESİ

HAYRİYE TATLI DOĞAN, Betül Aşan, Karabekır Ercan, Didem Şener Dede et autres